Evogene Ltd. (EVGN): Marketing Mix Analysis [Dec-2025 Updated]

You're looking at Evogene Ltd. right now, and honestly, it's a fascinating pivot point; after years as a holding company, they are betting the farm on their computational chemistry platform, ChemPass AI, aiming for that high-value licensing revenue. We need to see if this strategic shift-while cutting sales and marketing expenses to just $\text{approx. \$1.2 million}$ for the first nine months of 2025-is reflected in their market approach. With Q3 asset sales boosting the cash pile to $\text{approx. \$16 million}$ and a price-to-sales ratio sitting around $\text{1.40}$, the market is watching this transformation defintely closely. Let's break down the Product, Place, Promotion, and Price below to see if the new Evogene Ltd. strategy is priced right for the opportunity ahead.

Evogene Ltd. (EVGN) - Marketing Mix: Product

The product element for Evogene Ltd. (EVGN) centers on its proprietary technology engines, primarily ChemPass AI, which are applied across distinct life science verticals through internal development and subsidiary activities.

Core offering is ChemPass AI, a generative AI platform for small molecule design. This platform is described as the core engine for the company's strategy, focusing on the AI-driven discovery and optimization of small molecules. The computational capabilities include generative molecular design, virtual screening, and de novo multi-property molecule design.

AI platform targets both pharmaceutical and agricultural chemical discovery. The platform's application is broad, leveraging accumulated computational biology and chemistry expertise built over 20 years.

Commercial product is Casterra's superior castor seed varieties for industrial oil. Casterra's activity is a key revenue driver for Evogene Ltd. (EVGN) in the agricultural sector.

• Seed sales generated by Casterra were a primary driver of revenue in the first half of 2025.
• Casterra had approximately $2.0 million due from outstanding customers as of March 31, 2025, with the majority received in the second quarter of 2025.
• Revenues for the third quarter of 2025 decreased compared to the prior year, mainly due to reduced seed sales generated by Casterra during the quarter.

Biomica develops microbiome-based therapeutics, with a Phase 2 initiation planned for immuno-oncology. Biomica utilizes Evogene's MicroBoost AI tech-engine. The immuno-oncology program centers on the drug candidate BMC128.

• The Phase I clinical trial for BMC128 began with the first patient dosed in July 2022.
• The plan is for Biomica to complete its clinical trial for BMC128 by early 2026 and pursue potential partners for its development.
• Research and development expenses, net of non-refundable grants, for the nine months of 2025 were approximately $6.2 million, down from approximately $9.8 million in the nine months of 2024, partly due to reduced R&D expenses in Biomica.

AgPlenus's ag-chemical pipeline is being integrated into the core Evogene ChemPass AI activity. This integration represents a streamlining of operations to focus on the core AI engine.

The overall financial context for the product development activities as of late 2025 shows a strategic pivot. For the nine months ending September 30, 2025, total revenues were approximately $3.5 million. The consolidated cash and short-term bank deposits balance was approximately $16.0 million as of the end of the third quarter of 2025.

Evogene Ltd. (EVGN) - Marketing Mix: Place

The Place strategy for Evogene Ltd. (EVGN) is characterized by a decentralized, partnership-heavy model, leveraging global infrastructure for technology and localized networks for agricultural products.

Primary distribution is through strategic collaborations and licensing agreements with large industry partners. Evogene Ltd. focuses on developing core technology engines and then partnering or licensing for market penetration and scale. A significant recent transaction involved the sale of the majority of Lavie Bio's activity and the MicroBoost AI for Ag tech-engine to ICL, completed in July 2025, for a total of $18.71 million. Evogene Ltd. remains a major shareholder in Lavie Bio post-transaction. For its crop protection subsidiary, AgPlenus Ltd., revenues in the first quarter of 2024 included a license fee payment of $1.0 million under its collaboration with Bayer.

Casterra utilizes direct sales teams and local partnerships for seed distribution in markets like Brazil. Casterra Ag Ltd., an Evogene Ltd. subsidiary, focuses on high-yield castor seed varieties, employing a strategy of engaging local seed producers. Strategic agreements were signed with existing and new seed producers in Brazil and Africa to bolster production capabilities. These agreements were expected to add approximately 400 tonnes of seed production capacity in 2024. Furthermore, Casterra is executing castor farming proof of concept trials for grain sales to crushing factories in Kenya and Brazil, working with local partners, with initial results anticipated in Q3 2025.

AI technology is delivered globally via a proprietary platform, exemplified by the Google Cloud partnership. Evogene Ltd.'s core offering, ChemPass AI, is a proprietary generative AI engine for small molecule discovery. This platform's global delivery is underpinned by a strategic collaboration with Google Cloud, which provides the necessary infrastructure, including Vertex AI and GPUs on Google Compute Engine. The foundation model developed through this partnership is trained on a proprietary dataset of approximately 38 billion molecular structures.

Corporate headquarters and R&D hub are located in Rehovot, Israel. The central operational base for Evogene Ltd. is situated in Israel. The principal executive offices are located at 13 Gad Feinstein St., Park Rehovot, Rehovot, 7638517, Israel. The company also performs most of its testing at a leased "Greenhouse Research Center" outside Rehovot.

Distribution and operational footprint details include:

• Corporate Headquarters Location: Rehovot, Israel
• Key Agricultural Market for Seed Production: Brazil and Africa
• Expected Seed Production Increase from 2024 Agreements: ~400 tonnes
• AI Model Training Data Size: ~38 billion molecular structures
• Cash Position as of September 30, 2025: $16.0 million

Evogene Ltd. (EVGN) - Marketing Mix: Promotion

Promotion for Evogene Ltd. centers heavily on communicating its strategic shift toward its core technological asset, the ChemPass AI platform. Investor relations activities are clearly geared toward framing the company as a focused, AI-driven entity in computational chemistry, moving away from its previous, more diversified structure.

Investor relations focus on the strategic pivot to the high-value ChemPass AI platform. This involved direct engagement with the financial community to explain how this proprietary generative AI tech-engine is maximizing value across the pharmaceutical and agriculture industries. The CEO, Ofer Haviv, was the primary messenger for this narrative shift.

Public communication emphasizes 'Real-World Innovation' and 90% precision in molecule design. This messaging highlights the technological superiority of the ChemPass AI foundation model, which was developed in collaboration with Google Cloud. The precision claim is a key differentiator against traditional discovery methods.

The company has demonstrably tightened its spending on outreach efforts. Sales and marketing expenses were significantly reduced to approximately $1.2 million for the first nine months of 2025. This reduction reflects the organizational realignment completed by the end of the second quarter of 2025, streamlining activities outside the core focus areas.

Promotion includes participation in financial conferences like the H.C. Wainwright Global Investment Conference. The in-person presentation by the President and CEO took place at the H.C. Wainwright 27th Annual Global Investment Conference in New York, scheduled for Wednesday, September 10, 2025, at 1:00 PM ET. This provided a platform to detail the ChemPass AI strategy to interested investors.

Here's a quick look at the key promotional and related financial metrics as of late 2025:

The communication strategy is underpinned by specific technological claims and financial discipline:

• Focus on maximizing value from the ChemPass AI tech-engine.
• Highlighting the model's ability to address complex real-world constraints.
• Cost reduction plan completion by the end of the second quarter of 2025.
• Availability for one-on-one meetings with management at key conferences.

The messaging clearly aims to build confidence in the AI platform's commercial potential, which is key for attracting strategic partnerships and investment capital.

Evogene Ltd. (EVGN) - Marketing Mix: Price

You're looking at how Evogene Ltd. prices its value proposition, which is a blend of direct product sales and the monetization of its intellectual property through licensing. The pricing strategy here isn't just about setting a sticker price; it's deeply tied to the perceived value of its computational biology platform, ChemPass AI, and the success of its subsidiaries like Casterra.

Here's a quick look at some key financial metrics that frame the pricing environment for Evogene Ltd. as of late 2025:

The revenue model is fundamentally a mix of product sales, notably from Casterra seeds, and technology licensing fees from its various ventures. For the first nine months of 2025, total revenues were approximately $3.5 million, which was down from approximately $4.0 million in the same period last year. Still, the strategic asset sale of the majority of Lavie Bio's activity and the MicroBoost AI for Ag tech-engine to ICL provided a significant, non-recurring boost to the bottom line. This transaction generated net income, net, of approximately $7.9 million in the third quarter of 2025 alone, which is reflected in the final cash position.

To give you a clearer picture of the sales flow impacting the price-to-sales calculation, consider these points:

• Total revenues for the nine months ended September 30, 2025, were approximately $3.5 million.
• Revenue for the third quarter of 2025 was reported at approximately $312,000.
• Revenue for the first quarter of 2025 was approximately $2.4 million.

The market's valuation of Evogene Ltd.'s sales, as indicated by the price-to-sales ratio, stood at approximately 1.40 in late 2025. This ratio suggests how much investors are willing to pay for every dollar of reported sales, reflecting confidence in the underlying technology despite the recent revenue dip from the wind-down of some subsidiaries. Furthermore, the company's cash and short-term bank deposits balance as of September 30, 2025, was approximately $16 million, a figure bolstered by the asset sales proceeds, which certainly influences its short-term financial flexibility and pricing power.

Finance: draft 13-week cash view by Friday.